MedTrace Logo

Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus

NCT00362141 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2007-04-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether levetiracetam is safe and well tolerated by patients while suffering a status epilepticus. Levetiracetam is added to the standard treatment of patients with this disease.

Conditions

  • Status Epilepticus

Interventions

DRUG

levetiracetam (add-on)

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Medical Center Haaglanden

    lead OTHER

Principal Investigators

  • Charles Vecht, MD, PhD · Medical Centre Haaglanden

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Completion
2008-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00362141 on ClinicalTrials.gov